Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 21st European Biotechnology Congress Holiday Inn Vinogradovo, Moscow, Russia.

Day 2 :

Keynote Forum

Sergey Suchkov

I M Sechenov First Moscow State Medical University, Russia

Keynote: Antibodies with functionality as a new generation of translational tools to monitor, to predict and to prevent demyelination

Time : 10:00-10:40

OMICS International Euro Biotechnology 2018 International Conference Keynote Speaker Sergey Suchkov photo
Biography:

Sergey Suchkov graduated from Astrakhan State Medical University and was awarded with MD and maintained his PhD and Doctor’s degree. He was working for Helmholtz Eye Research Institute and Moscow Regional Clinical Research Institute. He was a Secretary-in-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. Currently, he is a Director of Center for Personalized Medicine, Sechenov University; Chair of the Department for Translational Medicine, Moscow Engineering Physics University and Secretary General of United Cultural Convention, Cambridge, UK. He is a Member of the New York Academy of Sciences; American Chemical Society; American Heart Association; AMEE, Dundee, UK; EPMA, Brussels, EU; PMC, Washington, DC, USA and ISPM, Tokyo, Japan.

Abstract:

Abs against myelin basic protein/MBP endowing with proteolytic activity (Ab-proteases with functionality) is of great value to monitor demyelination to illustrate the evolution of multiple sclerosis (MS). Anti-MBP auto-Abs from MS patients and mice with EAE exhibited specific proteolytic cleavage of MBP which, in turn, markedly differed between: MS patients and healthy controls; different clinical MS courses and; EDSS scales of demyelination to correlate with the disability of MS patients to predict the transformation prior to changes of the clinical course. Ab-mediated proteolysis of MBP was shown to be sequence-specific whilst demonstrating five sites of preferential proteolysis to be located within the immunodominant regions of MBP and to fall inside into 5 sequences fixed. Some of the latter (with the highest encephalitogenic properties) were proved to act as a specific inducer of EAE and to be attacked by the MBP-targeted Ab-proteases in MS patients with the most severe (progradient) clinical courses. The other ones whilst being less immunogenic happened to be EAE inducers very rare but were shown to be attacked by Ab-proteases in MS patients with moderate (remission-type) clinical courses. The activity of Ab-proteases was first registered at the subclinical stages 1-2 years prior to the clinical illness. About 24% of the direct MS-related relatives were seropositive for low-active Ab-proteases from which 22% of the seropositive relatives established were being monitored for 2 years whilst demonstrating a stable growth of the Ab-associated proteolytic activity. Moreover, some of the low-active Ab-proteases in persons at MS-related risks (at subclinical stages of MS), and primary clinical and MRT manifestations observed were coincided with the activity to have its mid-level reached. Registration in the evolution of highly immunogenic Ab-proteases would illustrate either risks of transformation of subclinical stages into clinical ones, or risks of exacerbations to develop. The activity of Ab-proteases in combination with the sequence-specificity would confirm a high subclinical and predictive (translational) value of the tools as applicable for personalized monitoring protocols. Ab-proteases can be programmed and re-programmed to suit the needs of the body metabolism or could be designed for the development of principally new catalysts with no natural counterparts. Further studies on targeted Abmediated proteolysis may provide a translational tool for predicting demyelination and thus the disability of the MS patients.

Keynote Forum

Igor l Katkov

Belgorod National State Research University, Russian Federation

Keynote: KrioBlastTM-3 - a three module system for efficient cryopreservation of unfreezable cells
OMICS International Euro Biotechnology 2018 International Conference Keynote Speaker Igor l Katkov photo
Biography:

Igor L Katkov is a trained biophysicist with 30+ years of experience in cryobiology and cryogenic engineering. His last years of research have been focused on the fundamental aspects of kinetic vitrification (K-VF) as well on designing the practical system for K-VF KrioBlast™ (in cooperation with V F Bolyukh). Currently, the Head of the Laboratory of the Amorphous state at the Belgorod National Research University BelSU, Russia. He has recently accepted a Professor level position as the Head of the Laboratory of Cryobiology at the V I Kulakov Research Center of Obstetrics, Gynecology and Perinatology (RCGOP), Moscow, Russia and Chief Scientific Officer of Celltronix, San Diego, CA, USA.

Abstract:

As we have stated before, there are 5 basics ways of achieving long-term storage, which ALL essentially lead to vitrification of cells, namely: slow freezing (SF), equilibrium vitrification (E-VF), kinetic vitrification (K-VF), freeze-drying (lyophilization), and va San Diego vacuum/air flow drying at temperatures above 0oC (xeropreservation). Previously, we presented KrioBlast-2, a pilot version of the KrioBlast™ platform for cryopreservation by kinetic (very fast) vitrification. One of the major advantages of K-VF over the existing approach for vitrification (E-VF) is that K-VF does not need the high concentrations of potentially toxic and intracellular vitrificants (also called: cryoprotectants, which is not exactly correct in this case) such as DMSO, ethylene glycol, dimethyl sulfamide. The pilot experiments on human pluripotent stem cells and spermatozoa, which showed an equally excellent (80-90% of the untreated control), were presented. The other key advantage of K-VF is its universality so the system is equally suitable for any kind of cells and tissues as soon as the characteristic thermal time of the system, which basically depends on the geometry of the cryo container with the sample, is sufficiently short. In this presentation, we will present the future development, the industrial three module system KrioBlast-3 that comprises 1) the cooling chamber for hyperfast cooling, 2) the intermediate module for shipment or long term storage in liquid nitrogen, and 3) the rewarming module. The second module has two port sites for the cooling and the rewarming modules so the system resembles a space station. All operations of cooling, storage/shipment, and warming are done without any contact of the sample with the ambient environment. The specific cryo containers for K-VF, namely VitriPlateTM, VitriCombTM, and VitriScanTM for vitrification of cells in suspension, packed in straws, and attached to surface in multiwell systems respectively are also discussed.